PDS Biotechnology Corp — Director's Dealing 2016

Aug 9, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2016-08-05

Reporting Person: MIDDLEKAUFF W BRADFORD (Senior VP, GC and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-05	Common Stock	P	9857	$9.48	Acquired	9857	Direct
2016-08-08	Common Stock	P	143	$9.43	Acquired	10000	Direct

Footnotes

F1: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $9.42 to $9.60 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.